<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05082662</url>
  </required_header>
  <id_info>
    <org_study_id>974-2020</org_study_id>
    <nct_id>NCT05082662</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study to Compare Diclofenac Potassium Coated Tablet (50 mg Diclofenac Potassium) Versus Cataflam® 50 Coated Tablet (50 mg Diclofenac Potassium), in Healthy Subjects Under Fasting Condition</brief_title>
  <official_title>Randomized, Four-way, Four-period, Fully-replicated, Single Oral Dose, Open-label, Crossover, Bioequivalence Study to Compare Diclofenac Potassium Coated Tablet (50 mg Diclofenac Potassium) Versus Cataflam® 50 Coated Tablet (50 mg Diclofenac Potassium), in Healthy Subjects Under Fasting Condition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmactive Ilac Sanayi ve Tic A.S.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharmactive Ilac Sanayi ve Tic A.S.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, four-way, four-period, fully-replicated, single oral dose, open-label, crossover,&#xD;
      bioequivalence study to compare Diclofenac Potassium coated tablet (50 mg Diclofenac&#xD;
      Potassium) versus Cataflam® 50 coated tablet (50 mg Diclofenac Potassium), in healthy&#xD;
      subjects under fasting condition&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 25, 2020</start_date>
  <completion_date type="Actual">September 16, 2020</completion_date>
  <primary_completion_date type="Actual">September 16, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax)</measure>
    <time_frame>10 hours</time_frame>
    <description>Statistical analysis of primary endpoints will include descriptive statistics, Analysis of Variance (ANOVA), and Confidence Interval (CI). The average bioequivalence of the products is concluded if the two-sided 90 % CI for the test to reference ratio of the population means is within 80.00 - 125.00 % for each of the Ln-transformed data for Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>10 hours</time_frame>
    <description>Statistical analysis of primary endpoints will include descriptive statistics, Analysis of Variance (ANOVA), and Confidence Interval (CI). The average bioequivalence of the products is concluded if the two-sided 90 % CI for the test to reference ratio of the population means is within 80.00 - 125.00 % for each of the Ln-transformed data for AUC0-t</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-∞</measure>
    <time_frame>10 hours</time_frame>
    <description>Statistical analysis of primary endpoints will include descriptive statistics, Analysis of Variance (ANOVA), and Confidence Interval (CI). The average bioequivalence of the products is concluded if the two-sided 90 % CI for the test to reference ratio of the population means is within 80.00 - 125.00 % for each of the Ln-transformed data for AUC0-∞</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>10 hours</time_frame>
    <description>The descriptive statistics including Maximum, Minimum and Median values will be measured for Tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thalf</measure>
    <time_frame>10 hours</time_frame>
    <description>Thalf was calculated from 0.693/ λz</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kelimination</measure>
    <time_frame>10 hours</time_frame>
    <description>The terminal elimination rate constant (Kelimination or λz) was estimated for each subject and for each treatment via linear regression of the last points (at least three points will be used) at the terminal phase of the log-concentration versus time curve of each subject</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure (safety and tolerability)</measure>
    <time_frame>At pre-dosing, 2, 4, 6, 8, and 10 hours post dosing, ± 45 minutes of scheduled time</time_frame>
    <description>Clinically significant abnormal deviations. Normal range of blood pressure &gt; 90/60 and &lt;140/90 mmHg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse (safety and tolerability)</measure>
    <time_frame>At pre-dosing, 2, 4, 6, 8, and 10 hours post dosing, ± 45 minutes of scheduled time</time_frame>
    <description>Clinically significant abnormal deviations. Normal range of Pulse 60-100 bpm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Temperature(safety and tolerability)</measure>
    <time_frame>At pre-dosing; 4, and 10 hours post dosing, ± 45 minutes of scheduled time</time_frame>
    <description>Clinically significant abnormal deviations. Normal range of temperature 36.5-37.5 ºC.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Non-steroidal Anti-inflammatory (NSAID)</condition>
  <condition>Analgesic</condition>
  <condition>Antipyretic</condition>
  <arm_group>
    <arm_group_label>Diclofenac Potassium coated tablet (50 mg Diclofenac Potassium)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cataflam® 50 coated tablet (50 mg Diclofenac Potassium)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diclofenac Potassium coated tablet (50 mg Diclofenac Potassium)</intervention_name>
    <description>One Diclofenac tablet was administered orally.</description>
    <arm_group_label>Cataflam® 50 coated tablet (50 mg Diclofenac Potassium)</arm_group_label>
    <arm_group_label>Diclofenac Potassium coated tablet (50 mg Diclofenac Potassium)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cataflam® 50 coated tablet</intervention_name>
    <description>One Diclofenac tablet was administered orally.</description>
    <arm_group_label>Cataflam® 50 coated tablet (50 mg Diclofenac Potassium)</arm_group_label>
    <arm_group_label>Diclofenac Potassium coated tablet (50 mg Diclofenac Potassium)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The subject is aged between eighteen &amp; fifty years (18 - 50).&#xD;
&#xD;
          -  The subject is within the limits for his height &amp; weight as defined by the body mass&#xD;
             index range (18.5 - 30.0 Kg/m2).&#xD;
&#xD;
          -  The subject is willing to undergo the necessary pre- &amp; post- medical examinations set&#xD;
             by this study.&#xD;
&#xD;
          -  The results of medical history, vital signs, physical examination &amp; conducted medical&#xD;
             laboratory tests are normal as determined by the clinical investigator.&#xD;
&#xD;
          -  The subject tested negative for hepatitis (B &amp; C) viruses and Human Immunodeficiency&#xD;
             Virus (HIV).&#xD;
&#xD;
          -  There is no evidence of psychiatric disorder, antagonistic personality and poor&#xD;
             motivation, emotional or intellectual problems likely to limit the validity of consent&#xD;
             to participate in the study or limit the ability to comply with protocol requirements.&#xD;
&#xD;
          -  The subject is able to understand and willing to sign the informed consent form.&#xD;
&#xD;
          -  For female subjects: negative pregnancy test and the woman is using two reliable&#xD;
             contraception methods.&#xD;
&#xD;
          -  The subject has normal gastrointestinal, cardiovascular system and ECG recording.&#xD;
&#xD;
          -  The subject kidney and liver (AST &amp; ALT enzymes) functions tests are within normal&#xD;
             range.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The subject is a heavy smoker (more than 10 cigarettes per day).&#xD;
&#xD;
          -  The subject has suffered an acute illness one week before dosing.&#xD;
&#xD;
          -  The subject has a history of or concurrent abuse of alcohol.&#xD;
&#xD;
          -  The subject has a history of or concurrent abuse of illicit drugs.&#xD;
&#xD;
          -  The subject has a history of hypersensitivity and/or contraindications to the study&#xD;
             drug and any related compounds.&#xD;
&#xD;
          -  The subject has been hospitalized within three months before the study or during the&#xD;
             study.&#xD;
&#xD;
          -  The subject is vegetarian.&#xD;
&#xD;
          -  The subject has consumed caffeine or xanthine containing beverages or foodstuffs&#xD;
             within two days before dosing and until 10 hours after dosing in all study periods.&#xD;
&#xD;
          -  The subject has taken a prescription medication within two weeks or even an over the&#xD;
             counter product (OTC) within one week before dosing in each study period and any time&#xD;
             during the study, unless otherwise judged acceptable by the clinical investigator.&#xD;
&#xD;
          -  The subject has taken grapefruit containing beverages or foodstuffs within seven (7)&#xD;
             days before first dosing and any time during the study.&#xD;
&#xD;
          -  The subject has been participating in any clinical study (e.g. pharmacokinetics,&#xD;
             bioavailability and bioequivalence studies) within the last 80 days prior to the&#xD;
             present study.&#xD;
&#xD;
          -  The subject has donated blood within 80 days before first dosing.&#xD;
&#xD;
          -  The subject has a history or presence of cardiovascular, pulmonary, renal, hepatic,&#xD;
             gastrointestinal, hematological, endocrinal, immunological, dermatological,&#xD;
             neurological, musculoskeletal or psychiatric diseases.&#xD;
&#xD;
          -  The subject has consumed drugs that may affect pharmacological or pharmacokinetic&#xD;
             properties (Voriconazole and Aspirin) two weeks before dosing, during the study and&#xD;
             two weeks after dosing.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>ACDIMA Biocenter</name>
      <address>
        <city>Amman</city>
        <country>Jordan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Jordan</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 14, 2021</study_first_submitted>
  <study_first_submitted_qc>October 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2021</study_first_posted>
  <last_update_submitted>October 16, 2021</last_update_submitted>
  <last_update_submitted_qc>October 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diclofenac</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

